BACKGROUND: Mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) can cause congenital bilateral absence of the vas deferens (CBAVD) as a primarily genital form of cystic ®brosis. The spectrum and frequency of CFTR mutations in Turkish males with CBAVD is largely unknown. METHODS: We investigated 51 Turkish males who had been diagnosed with CBAVD at the Hacettepe University, Ankara, for the presence of CFTR gene mutations by direct sequencing of the coding region and exon/intron boundaries. RESULTS: We identi®ed 27 different mutations on 72.5% of the investigated alleles. Two-thirds of the patients harboured CFTR gene mutations on both chromosomes. Two predominant mutations, IVS8-5T and D1152H, accounted for more than one-third of the alleles. Five mutations are described for the ®rst time. With one exception, all identi®ed patients harboured at least one mutation of the missense or splicing type. Presently available mutation panels would have uncovered only 7±12% of CFTR alleles in this population cohort. CONCLUSIONS: Although cystic ®brosis is relatively rare in Turkey, CFTR mutations are responsible for the majority of CBAVD in Turkish males. Because of a speci®c mutation pro®le, a population-speci®c panel should be recommended for targeted populations such as CBAVD in Turkey or elsewhere.
Introduction
Congenital bilateral absence of the vas deferens (CBAVD) is a frequent cause of obstructive azoospermia and is responsible for 1±2% of male infertility (Mak and Jarvi 1996) . CBAVD is an autosomal recessive condition that has been classi®ed as a primarily genital form of cystic ®brosis (Anguiano et al., 1992; Oates and Amos 1994) . Cystic ®brosis (CF), in its classic form, is characterised by chronic pulmonary disease, pancreatic insuf®ciency, intestinal obstruction, male infertility and elevated sweat chloride (Welsh et al., 2001) . However, its clinical expression can vary widely and partly depends on the nature of the underlying mutation genotype . The gene responsible for CF encodes the Cystic Fibrosis Transmembrane conductance Regulator (CFTR, syn. ABCC7), that is a cAMP regulated chloride channel found in the apical membrane of epithelial cells (Welsh et al., 2001) . More than 1000 CFTR gene mutations have been reported so far (http://www.genet.sickkids.on.ca) and distinct mutation genotypes have been reported in patients with full-blown CF and with isolated CBAVD (Anguiano et al., 1992; Chillo Ân et al., 1995; Costes et al., 1995; Dumur et al., 1996; Do Èrk et al., 1997; Casals et al., 2000; Claustres et al., 2000) .
Little is known about the spectrum and frequency of CFTR gene mutations in Turkey. Classic cystic ®brosis is less common in the Turkish population than in Central Europe, with an estimated incidence of about 1:10 000 newborns, but other entities such as CBAVD have not been investigated yet. Two recent studies have provided evidence for an extensive allelic heterogeneity in Turkish patients with classic CF (Onay et al., 2001; Kilinc Ë et al., 2002) . We here report the results of a detailed investigation of CFTR mutation genotypes in 51 Turkish CBAVD patients. We have identi®ed by direct sequencing a high frequency of different CFTR gene alterations and a mutational spectrum that is distinct from other populations.
Materials and methods
Patients A total of 51 CBAVD patients had been referred to our laboratory at the Department of Medical Biology, Hacettepe University, Ankara, Turkey, during the years 1996±2000. All patients originated from Anatolia. These patients were diagnosed before as having obstructive azoospermia at different urology departments in Ankara. The diagnosis of CBAVD was based upon clinical examination with impalpable vas deferens and normal or nearly normal testicular volume. Transrectal ultrasonography showed seminal vesicle abnormalities such as hypoplasia and aplasia. Testicular biopsies demonstrated normal or hypospermatogenetic activity. Renal agenesis was tested in 13 patients, two were found with unilateral renal agenesis and one patient had chronic renal insuf®ciency and agenesis of both kidneys. All patients were between 28 and 45 years old. All males presented with no discernible lung disease or presentation of disease in other organs. Consanguinity of the parents was recorded in 8 of 32 patients for whom data were available. None of the patients had a family history of cystic ®brosis, and only patients who were apparently unrelated were included in this study.
Mutation analysis
Genomic DNA was extracted from peripheral blood leukocytes by routine procedures. All 51 samples were ®rst screened for the DF508 and 1677delTA mutations in exon 10 with PCR followed by polyacrylamide gel electrophoresis. We next screened for six further CFTR gene mutations of the coding region and¯anking intron sequences by previously described restriction-enzyme based methods: G85E, D110H, R347H, 2789+5G®A, D1152H, N1303K (Do Èrk et al., 1994a (Do Èrk et al., , 1997 . One deep intronic mutation 3849+10kBC®T was tested by restriction enzyme analysis (Highsmith et al., 1994) and four large genomic deletions CFTRdele2(5kB), CFTRdele2(ins186), CFTRdele2,3(21kB) and 3120+1kBdel8.6kB were screened using speci®c primer pairs (Lerer et al., 1999; Do Èrk et al., 2000a,b) . Missense polymorphism M470V in exon 10 was typed by HphI restriction enzyme analysis and the exon 9 and its¯anking intron regions were sequenced in all samples to determine the status of polyvariant alleles that modulate the splicing and maturation of CFTR . The 33 samples with no or only one clearly pathogenic mutation identi®ed after this initial screening were then subjected to direct sequencing of the entire coding sequence and all intron/exon boundaries of the CFTR gene using dye terminator chemistry and capillary electrophoresis on an ABI 310 genetic analyser (Applied Biosystems). We used published primer pairs for PCR and sequencing of most of the 27 exons (Zielenski et al., 1991) except for the following primers:
5¢-GGTCTTTGGCATTAGGAGCTTG-3¢ and 5¢-TCAGTTGCA-AGTAGATGTGGC-3¢ (exon 1, annealing 59°C); 5¢-GGAA-GATGAAATTGTGTGTACCTTG-3¢ and CCACTACCATAATG-CTTGGGAG-3¢ (exon 14b, annealing 58°C); 5¢-CTACCCCAT-GGTTGAAAAGCTG-3¢ and 5¢-GCAGGAACTATCACATGTGAG-3¢ (exon 23, annealing 58°C); 5¢-CTGACCTGCCTTCTGTCCCAG-3¢ and 5¢-CTGAGGCAGAGGTAACTGTTCC-3¢ (exon 24, annealing 61°C). Finally, the 5¢-UTR and minimum promoter region were Mutations were designated following the recommended nomenclature (Beaudet and Tsui, 1993) except for the IVS8-(T) n alleles which are named according to the number of their residual thymidines (Chu et al., 1993) . 
Results
A total of 27 mutations was identi®ed on 74 of the 102 alleles, as listed in Table I . Two mutations were found to be very common in Turkish CBAVD patients: ®rst, the IVS8-5T allele was observed, with TG12 or TG13 haplotypes, on 20 chromosomes thus con®rming the association of this splice site variant with CBAVD in Turkish patients. Secondly, the D1152H mutation in exon 18 was uncovered on 15 chromosomes, thereby revealing an unexpected high frequency of this missense substitution in Turkish CBAVD patients. Screening for the IVS8-5T and D1152H mutations together led to the identi®cation of more than one-third of alleles. The D1152H mutation was found in the homozygous state in ®ve patients and the IVS8-5T allele was found homozygous in four patients (Table II) . Missense and splice site alterations were also predominant among the other 25 identi®ed mutations whereas truncating mutations and the DF508 allele played a minor role (Table I) . There was one patient compound heterozygous for two truncating mutations (1677delTA/E831X), but all other patients with completely resolved mutation genotype carried a missense or splicing mutation on at least one allele. Several mutations were already known as`mild' alleles in cystic ®brosis, e.g. D110H, R347H or 2789+5G®A, and have been described previously in studies of patients with CBAVD. A few other substitutions, e.g. R74W, 2751-15C®G, L997F, are not classic cystic ®brosis mutations but we cannot exclude the possibility that they may contribute to a CBAVD phenotype, and the L997F substitution was reported to be associated with mild forms of cystic ®brosis such as pancreatitis (Gomez Lira et al., 2000) . An unusual variant of the polyT tract in intron 8 was also identi®ed, i.e. the IVS8-6T allele ( Figure 1A) , and was considered as a candidate mutation for CBAVD in one patient who also was heterozygous for the CFTRdele2(ins186) deletion with no other mutation detected.
Five mutations are described here for the ®rst time: 1767del6, 3041-13del7, 3041-15T®G, I853F and G1130A. The ®rst three were found in the homozygous state. The 1767del6 mutation results in a two-amino-acid deletion within the ®rst nucleotide binding fold of CFTR adjacent to the conserved ABC signature termed`Walker C' motif. The deletion 3041-13del7 and the substitution 3041-15T®G both disrupt the polypyrimidine tract of the intron 15 acceptor splice site and thus may result in aberrant splicing ( Figure 1B) . The missense mutations I853F and G1130A lead to subtle amino acid alterations in less conserved portions of the CFTR protein.
Although we cannot prove that these ®ve new mutations are pathogenic, no other sequence alteration was identi®ed through direct sequencing in these patients.
In summary, this study led to the identi®cation of 27 CFTR gene mutations and presumably pathogenic alterations on 72.5% of chromosomes from 51 Turkish CBAVD patients. Two mutant alleles were identi®ed in 34 patients (66.7%). One mutant allele was identi®ed in six patients (11.7%), of whom two carried clearly pathogenic mutations (DF508 and R347H, respectively) and four harboured unclassi®ed variants. No mutations were found in 11 patients (21.6%), including the three patients with known renal malformations.
Discussion
Mutation analysis of the CFTR gene has become a standard procedure for couples seeking genetic testing before assisted reproduction if the male infertility is caused by obstructive azoospermia. Because lung disease and other CF-like symptoms may develop later in life in those young adults who are mutation carriers, careful work-up and counselling is mandatory. However, while the spectrum and frequency distribution of CFTR gene mutations in most patients of European descent Mutation genotypes were designated following the recommended nomenclature (Beaudet and Tsui, 1993) . The IVS8-(TG) m T n haplotypes were named by the number of upstream TG dinucleotides followed by the number of consecutive thymidines (Do Èrk et al., 1994b; Costes et al., 1995) . The M470V alleles were designated M for nucleotide A at position 1540 and V for nucleotide G at position 1540. Genotype frequencies are given as numbers and, in brackets, as percentages of the total cohort (51 patients).
has been the subject of extensive research, information is scarce about other populations, even those at the European± Asian border, and thus the ef®cacy of the present diagnostic tools for genetic testing in Turkish couples is largely unknown. Two recent reports have demonstrated a marked heterogeneity of CFTR mutations in Turkish patients with classic cystic ®brosis. In the ®rst study of 98 families, Onay et al., (2001) have described 28 different CFTR mutations, including the IVS8-5T allele, on 105 of 168 CF chromosomes (62.5%) after scanning the whole coding region using a multiplex heteroduplex method. In the second study, Kilinc Ë et al., (2002) investigated 83 Turkish CF patients and reported 36 different mutations, excluding the IVS8-5T allele, that accounted for 125 of the 166 CF chromosomes (75%). The most common mutation DF508 was present on about one in four alleles in both reports, this is a signi®cantly lower frequency than in CF patients from Central European populations. The results of this study re¯ect the high allelic heterogeneity of CFTR gene mutations, although two mutations, IVS8-5T and D1152H, were found to be very common in Turkish CBAVD patients. First, the IVS8-5T allele was observed on 19.6% of all chromosomes. This polythymidine tract deletion is known as a splicing mutation with reduced penetrance (Chillo Ân et al., 1995; Costes et al., 1995; and is found at an allele frequency of only 3±5% in the general Turkish population (Onay et al., 2001; Kilinc Ë et al., 2002) . Consistent with previous reports (Costes et al., 1995; Do Èrk et al., 1997; Cuppens et al., 1998) , we ®nd that the IVS8-5T allele in CBAVD patients is exclusively associated in cis with long IVS8-(TG) 12±13 tracts which have been shown to increase the extent of exon 9 skipping induced by the 5T variant Niksic et al., 1999; Buratti et al., 2001) . It has previously been found that IVS8-5T is a recurrent mutation on different ethnic backgrounds, thus our study corroborates the suggestion that it may contribute substantially to the etiology of CBAVD worldwide (Do Èrk et al., 1997; Lissens et al., 1999) . Secondly, the D1152H missense substi- tution was uncovered on 14.7% of all chromosomes. This ®nding was unexpected because this mutation has not been detected in Turkish CF patients before (Onay et al., 2001; Kilinc Ë et al., 2002) . It has, however, been previously observed in CBAVD patients of diverse ethnicities at low frequencies (Do Èrk et al., 1997; Kerem et al., 1997; Claustres et al., 2000) and was initially reported as a mild cystic ®brosis mutation. In vitro studies have shown that the D1152H substitution does not interfere with the maturation of the CFTR protein but strongly reduces its cAMP-activated chloride conductance (Vankeerberghen et al., 1998) which may provide the basis for a mild expression of disease. Our results implicate D1152H as a common missense mutation in Turkey which appears to be speci®cally associated with CBAVD, perhaps comparable to the role of the R117H missense substitution in Central Europe (Gervais et al., 1993; Do Èrk et al., 1997) . All D1152H alleles appeared to be linked with the same haplotype comprising the IVS8-7T(TG) 11 and Val470 alleles (Table II) . Screening for the IVS8-5T and D1152H mutations together led to the identi®-cation of more than one-third of alleles in Turkish CBAVD males.
Most of the less frequent mutations were also of the missense or splicing type and, beyond the IVS8-5T allele, four other putative splicing mutations have been identi®ed that also target a polypyrimidine tract. The IVS8-6T allele constitutes a new member of the growing family of polyT variants in intron 8 and may have clinical implications. Although the 6T allele has ®rst been observed in an apparently healthy female carrier seeking assisted reproduction , it could nevertheless be a CBAVD causing mutation. With the four alleles that have previously been identi®ed in intron 8 of the CFTR gene (T9, T7, T5 and T3), the ef®ciency of the splice acceptor site usage consistently decreases with shorter polythymidine tracts which results in a lower than normal level of full-length CFTR mRNA (Chu et al., 1993; Mak et al., 1997; Teng et al., 1997; Larriba et al., 1998; Buratti et al., 2001) . The 6T allele can be predicted to affect splicing to a degree between the 5T and 7T alleles and thus it could represent a low-penetrance mutation, at the border between health and mild disease. The other polypyrimidine tract variants 2752-15C®G, 3041-15T®G, and 3041-13del7 all reduce the maximum entropy score of the respective acceptor splice sites (Yeo and Burge 2004;  http://genes.mit.edu/ burgelab/maxent/Xmaxentscan_scoreseq_acc.html), but the quantitative impact of these mutations on the accuracy and ef®ciency of splicing remains to be determined.
The observation that almost every Turkish CBAVD patient with identi®ed mutation genotype harboured a missense or splicing mutation on at least one allele is in line with previous reports of such a distinction between mutation genotypes in CF and CBAVD (Do Èrk et al., 1997; Claustres et al., 2000) . The ®rst exception is one patient in our study who is a compound heterozygote for the two truncating mutations 1677delTA and E831X. Although early reports have suggested that CF patients with two null alleles may have milder lung disease compared with DF508 homozygotes (Gasparini et al., 1992; Wine, 1992) , such patients are generally pancreatic insuf®cient and previous studies of patients with isolated CBAVD have not revealed any patient carrying two truncating mutations, thus far (Do Èrk et al., 1997; Claustres et al., 2000) . It may thus be the particular genotype of our single case that confers an unusually mild phenotype. Exon 14a is the subject of alternative splicing (Hull et al., 1994; Bienvenu et al., 1996) and the mutation E831X at the ®rst base of this exon may increase its in-frame skipping. Such a by-pass of a premature termination codon has been shown to ameliorate the disease phenotype in other clinical conditions (Morisaki et al., 1993; Ginjaar et al., 2000; Su et al., 2000) .
Our study detected CFTR gene mutations on both alleles in two-thirds of the Turkish CBAVD males. This is comparable with thorough studies of European CBAVD patients as well as with the detection rate obtained for Turkish CF patients. Eleven patients, including three with con®rmed renal agenesis, remained with no mutation identi®ed after sequencing all exons. The reasons for the incomplete detection could not be fully established but may be related to some heterogeneity in the etiology of CBAVD (Rave-Harel et al., 1995; McCallum et al., 2001) . There is evidence that the prevalence of CFTR mutations is signi®cantly reduced in patients who have CBAVD accompanied by renal agenesis (Augarten et al., 1994; Schlegel et al., 1996; Do Èrk et al., 1997; Casals et al., 2000; McCallum et al., 2001) . It is also possible that some unknown mutations outside of the analysed regions account for a proportion of unidenti®ed alleles in our study and in Turkish CF patients (Onay et al., 2001; Kilinc Ë et al., 2002) . Despite these limitations, we believe that direct sequencing is the most sensitive of the presently available methods for a whole CFTR mutation genotyping in Turkish CBAVD patients. Any of today's commercially distributed kits would miss the majority of the mutant alleles in our patient cohort. For instance, the analysis of the 31 most common cystic ®brosis mutations found within the white population would have detected three mutations, accounting for 8 of the 102 alleles in the Turkish CBAVD patients (8%, compared with 31% in Canadian CBAVD males; Mak et al., 1999) . The ACMG 25 mutation panel that includes core mutations recommended for general population CF carrier screening, would also have detected three mutations on 7 of the 102 alleles in our cohort (7%; Grody et al., 2001 ). An extension of this panel to 100 CF mutations together with mass spectrometry analysis would have detected 7 mutations on 12 of the 102 alleles (12%; Wang et al., 2002) .
In conclusion, none of the currently used routine mutation panels is well-suited for Turkish couples seeking genetic testing before assisted reproduction. It would be desirable to have more population-speci®c mutation panels which could help to overcome the underdiagnosis of cystic ®brosis and other CFTR-related diseases in those countries where the mutational distribution does not match that of Central Europe. In this regard, a population-speci®c mutation panel including the D1152H mutation and the IVS8-5T allele should be highly recommended for Turkish CBAVD patients. Our data add to a growing body of evidence that CFTR mutations can have a substantial clinical impact also in populations where cystic ®brosis in its classic form may be infrequent. The spectrum of mutations and genotypes that we have presented here, includ-ing the identi®cation of a common missense mutation, should be useful to re®ne the diagnosis of CBAVD or other CFTRrelated diseases in patients of Turkish descent.
